Table 1 CD274 amplification prevalence vs. PD-L1 TPS, CPS, and IC positivity status.

From: A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases

PD-L1 cohort

CD274 prevalence

TPS+

1.53% (252/16,461)

TPS−

0.12% (31/26,457)

CPS+

1.36% (34/2495)

CPS−

0.09% (1/1080)

IC+

2.67% (24/900)

IC−

0.58% (8/1388)

Back to article page